People searching for a GHK-Cu dosage are usually looking for an amount to use. The evidence-based answer is that there is no established or approved systemic human dose for the copper peptide GHK-Cu. The human research that exists is almost entirely topical and cosmetic — described by the concentration of peptide in a cream, serum or gel rather than by an injected amount — and no health authority has approved GHK-Cu as a medicine with a defined dose. This article documents what has actually been investigated and at what quantities; it is a review of published research, not a recommendation.
What is GHK-Cu?
GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine (GHK) bound to a copper(II) ion. GHK occurs naturally in human plasma, where its concentration is reported to fall with age — from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60. It has been studied for decades for roles in skin remodelling, wound repair, antioxidant activity and broad modulation of gene expression. GHK-Cu is not an approved medicine in the UK, EU or US and is supplied strictly as a laboratory research reagent — the GHK-Cu research peptide we supply is lyophilised powder in 50mg and 100mg vials.
Is there an established GHK-Cu dosage?
There is no approved medical dose and no systemic (injectable) human dosing standard. What the literature describes instead is:
- Topical concentrations used in dermatological and cosmetic research — GHK-Cu formulated into creams, serums or gels at a percentage concentration.
- A registered clinical trial evaluating a topical GHK-Cu gel for skin wound healing (see below).
- Preclinical and laboratory work in animals and cultured cells.
A concentration in a topical product is not the same thing as a systemic dose, and none of this establishes an amount for injection or other administration.
GHK-Cu dosage investigated in human clinical research
Human research on GHK-Cu is dominated by topical application. Reported work is summarised in the peer-reviewed review literature and in trial registries:
| Setting | Model | Quantity investigated | Route | Reported focus |
|---|---|---|---|---|
| Topical GHK-Cu gel, acute skin wounds (NCT07437586) | Healthy adults (registered trial) | Topical gel vs matching vehicle | Topical | Whether it safely speeds healing of small standardised wounds |
| Cosmetic / dermatological formulations | Human skin | Peptide included at a percentage concentration in creams and serums | Topical | Skin appearance, barrier and remodelling markers |
In other words, human GHK-Cu data is reported as a formulation concentration applied to the skin, not as a measured internal dose. Rigorous, dose-controlled human trials remain limited, and a large share of the frequently-quoted figures come from cosmetic evaluations rather than regulated clinical trials — so specific percentage-improvement claims should be read with caution and are not reproduced here as dosing guidance.
Dose-escalation research
No published human dose-escalation programme (a designed low-to-high comparison with defined arms) exists for GHK-Cu. This is a key evidence gap: unlike some peptides that have Phase 2 trials comparing several fixed amounts, GHK-Cu has not been through that kind of regulated escalation study in humans.
Preclinical (animal and laboratory) research
Most mechanistic GHK-Cu evidence is preclinical:
- Cultured human cells: GHK has been reported to modulate the expression of a large number of human genes in fibroblast cultures, which underpins much of the interest in tissue remodelling. These are in-vitro concentrations in cell culture, not doses.
- Animal wound and tissue models: copper-peptide preparations have been applied topically or locally in animal models of wound and tissue repair.
These are preclinical and laboratory findings and cannot be interpreted as establishing an equivalent human dosage. Cell-culture and animal quantities do not translate into a human amount.
What did different dosage groups show?
Because human GHK-Cu research has not run formal multi-arm dose comparisons, there is no reliable published human dose–response curve. Cosmetic studies have compared different topical concentrations, but these are not regulated clinical dose-finding trials and are not summarised here as guidance. The registered wound-healing trial (NCT07437586) is a single-formulation comparison against vehicle rather than a dose-ranging study.
Safety and adverse events reported in research
In topical cosmetic use, GHK-Cu is generally described as well tolerated, with the main reported effects being transient, mild skin irritation or redness at the application site. Systemic safety data in humans is limited because there is no established systemic use; copper is an essential trace element but also one where excess is undesirable, which is one reason injectable or high-exposure use has not been characterised in controlled human studies. Negative or neutral findings are under-reported in this space, which itself is a limitation.
What the research does not tell us
- It does not provide a systemic or injectable human dose — human data is topical and concentration-based.
- A topical percentage concentration is not a dose and should not be treated as one.
- There are no formal human dose-escalation or dose–response trials.
- Much of the mechanistic evidence is in-vitro or animal, which does not translate to a human amount.
- There is no MHRA/EMA/FDA-approved indication or dose.
GHK-Cu research timeline
- 1970s–1980s — GHK identified as a naturally occurring copper-binding plasma peptide and studied for tissue-repair activity.
- 2018 — A peer-reviewed review consolidates gene-expression data, cataloguing GHK's broad effects on human gene activity in cultured cells.
- 2020s — A registered clinical trial (NCT07437586) evaluates a topical GHK-Cu gel versus vehicle for acute skin-wound healing.
Key takeaway
The human evidence for GHK-Cu is topical and concentration-based (creams, serums and a registered wound-healing gel), and the mechanistic evidence is largely in cultured cells and animals. There is no established systemic human dose, no formal human dose-escalation data, and no approval from the MHRA, EMA or FDA. The quantities described above are formulation concentrations and study parameters — not a personal dosing recommendation.
Research materials
PepSource supplies GHK-Cu as lyophilised powder in 50mg and 100mg vials, plus a made-to-order GHK-Cu pen refill cartridge. GHK-Cu is also a component of the GLOW Blend (BPC-157, GHK-Cu and TB-500) and the KLOW Blend (BPC-157, GHK-Cu, TB-500 and KPV). Every batch is independently third-party tested for HPLC purity and mass-spec identity, with certificates of analysis published by batch. Supplied strictly as laboratory research reagents — not for human or veterinary use.
References
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. PMC: PMC6073405.
- Topical GHK-Cu Gel for Acute Skin Wound Healing. ClinicalTrials.gov: NCT07437586.